Patents by Inventor Martin John Schnermann
Martin John Schnermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230382857Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary system are disclosed. Certain heptamethine cyanines exhibit biliary system specificity and methods for in vivo visualization of a biliary system of a subject are provided. The methods may be for diagnostic purposes and/or for visualization of biliary systems during surgery.Type: ApplicationFiled: July 25, 2023Publication date: November 30, 2023Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John SCHNERMANN, Peter C.W. KIM, Jaepyeong CHA, Roger Rauhauser NANI
-
Patent number: 11787764Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.Type: GrantFiled: February 14, 2019Date of Patent: October 17, 2023Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John Schnermann, Peter C. W. Kim, Jaepyeong Cha, Roger Rauhauser Nani
-
Patent number: 11781955Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: September 21, 2020Date of Patent: October 10, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Patent number: 11746086Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.Type: GrantFiled: February 18, 2021Date of Patent: September 5, 2023Assignee: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
-
Publication number: 20210198196Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.Type: ApplicationFiled: February 18, 2021Publication date: July 1, 2021Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
-
Publication number: 20210100919Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.Type: ApplicationFiled: February 14, 2019Publication date: April 8, 2021Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Martin John SCHNERMANN, Peter C.W. KIM, Jaepyeong CHA, Roger Rauhauser NANI
-
Patent number: 10961193Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.Type: GrantFiled: February 15, 2019Date of Patent: March 30, 2021Assignee: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
-
Publication number: 20210017132Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.Type: ApplicationFiled: February 15, 2019Publication date: January 21, 2021Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
-
Publication number: 20210010914Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: ApplicationFiled: September 21, 2020Publication date: January 14, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Patent number: 10876003Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.Type: GrantFiled: April 3, 2019Date of Patent: December 29, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
-
Patent number: 10874739Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: GrantFiled: December 20, 2019Date of Patent: December 29, 2020Assignee: The Unites States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
-
Patent number: 10830678Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: GrantFiled: August 7, 2015Date of Patent: November 10, 2020Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
-
Publication number: 20200121790Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Applicant: The United States of America, as represented by the Secretary Department of Health and Human ServiceInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
-
Patent number: 10561729Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: GrantFiled: August 7, 2017Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka
-
Publication number: 20190225811Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.Type: ApplicationFiled: April 3, 2019Publication date: July 25, 2019Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
-
Publication number: 20190167793Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: ApplicationFiled: August 7, 2017Publication date: June 6, 2019Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServiceInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
-
Patent number: 10280307Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.Type: GrantFiled: November 5, 2014Date of Patent: May 7, 2019Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
-
Publication number: 20180273758Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.Type: ApplicationFiled: November 5, 2014Publication date: September 27, 2018Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
-
Publication number: 20170122853Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.Type: ApplicationFiled: August 7, 2015Publication date: May 4, 2017Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
